Rush Medical College, Rush University Medical Center, Chicago, IL 60612, USA; Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.
Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.
Trends Mol Med. 2023 Apr;29(4):282-296. doi: 10.1016/j.molmed.2023.01.002. Epub 2023 Feb 15.
Glioblastoma (GBM) remains a fatal diagnosis despite the current standard of care of maximal surgical resection, radiation, and temozolomide (TMZ) therapy. One aspect that impedes drug development is the lack of an appropriate model representative of the complexity of patient tumors. Brain organoids derived from cell culture techniques provide a robust, easily manipulatable, and high-throughput model for GBM. In this review, we highlight recent progress in developing GBM organoids (GBOs) with a focus on generating the GBM microenvironment (i.e., stem cells, vasculature, and immune cells) recapitulating human disease. Finally, we also discuss the use of organoids as a screening tool in drug development for GBM.
尽管目前的治疗标准是最大限度的手术切除、放疗和替莫唑胺（TMZ）治疗，但胶质母细胞瘤（GBM）仍然是一种致命的诊断。阻碍药物开发的一个方面是缺乏能够代表患者肿瘤复杂性的合适模型。源自细胞培养技术的脑类器官为 GBM 提供了一个强大的、易于操作的、高通量的模型。在这篇综述中，我们重点介绍了近年来在开发 GBM 类器官（GBO）方面的进展，这些类器官侧重于生成能够重现人类疾病的 GBM 微环境（即干细胞、血管和免疫细胞）。最后，我们还讨论了类器官作为 GBM 药物开发中的筛选工具的应用。
